Bigbear Pharmaceutical·Medication Guide

• FDA Approves Cabozantinib Tablets for Previously Untreated Advanced Renal Cell Carcinoma

  December 19, 2017 — South San Francisco, CA — (Business Wire)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) ···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 101

• FDA Approves Cabozantinib for Treatment of Previously Treated Advanced Neuroendocrine Tumors

  March 31, 2025 (HealthDay) — According to a press release issued by the Dana-Farber Cancer Institute:The U.S. Food and Drug Administration (FDA) has a···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 114

• Is Cabozantinib a Chemotherapy Drug?

  Cabozantinib is not a chemotherapy drug; rather, it is a targeted therapy medication. It works by targeting specific enzymes that are typically closel···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 108

• Can Cabozantinib Cure Cancer?

  Cabozantinib cannot cure cancer. Cabozantinib is a tyrosine kinase inhibitor that is currently approved for the treatment of the following types of ca···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 125

• Mechanism of Action of Enasidenib for the Treatment of Acute Myeloid Leukemia (AML)

  Enasidenib is an oral targeted therapy used for acute myeloid leukemia (AML) that exerts its effects by blocking isocitrate dehydrogenase-2 (IDH2).Mec···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 105

• Enasidenib: Uses, Mechanism of Action, and Indications

  Enasidenib is an oral medication used to treat acute myeloid leukemia (AML) in adult patients. Acute myeloid leukemia (AML) is a type of cancer that a···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 120

• ​FDA Approves Enasidenib for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation

  August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 118

• FDA Warns That Leukemia Drug Enasidenib May Trigger Differentiation Syndrome

  On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 110

• Anagrelide: Prescription Information and Overview

  Anagrelide capsules, for oral administration, were first approved for marketing in the United States in 1997. Anagrelide is a thrombocytopenic agent i···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 128

• FDA Approves Osimertinib for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to an oral medication for the treatment of patients wit···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 118

• Osimertinib Receives Full FDA Approval for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  March 31, 2017 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Osimertinib (brand name: Tagrisso···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 97

• ​FDA Approves Osimertinib as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

  On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved the targeted therapy Osimertinib for the first-···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 99

• What Diseases Does Osimertinib Treat? Actions and Efficacy of Osimertinib

  Osimertinib is a tyrosine kinase inhibitor used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have been identified—via an FDA···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 100

• Osimertinib Approved in the U.S. for Adjuvant Treatment of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

  On December 21, 2020, AstraZeneca’s Osimertinib was approved in the United States for the adjuvant treatment of adult patients with early-stage epider···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 91

• US Approves Osimertinib in Combination with Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

  On February 19, 2024, AstraZeneca announced that its drug, osimertinib, has received approval in the United States for use in combination with chemoth···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 94